Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...

Silicon Valley Is in a Frenzy Over Bots That Build Themselves

Holding signs and banners reading Stop the AI Race and Don’t Build Skynet, the protesters marched through the city and gave ...
Forbes

The Most Important Idea In AI: Recursive Self Improvement

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
Insider Monkey

Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a ...
Benzinga.com

Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Reuters

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
CNBC

Cramer's Lightning Round: Recursion Pharmaceuticals 'has been horrendous'

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
GEN

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
STAT

Recursion CEO Chris Gibson out as company head after 12 years

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Insider Monkey

Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...